CDD-2789

• Target :

  TGF-beta/Smad|||ALK

• Related Pathways :

  Angiogenesis|||Stem Cells|||Tyrosine Kinase/Adaptors

• Bioactivity :

  CDD-2789 is a highly selective small molecule inhibitor that targets Activin receptor type 1 (ALK2, also known as ACVR1) . It effectively blocks the BMP and activin A-induced downstream phosphorylation reactions by inhibiting the ALK2/ALK1-mediated SMAD1/5 signaling pathway. In the NanoBRET cell model, CDD-2789 demonstrates an inhibitory activity with an IC50 value of 0.54 µM for ALK2. This compound holds potential for research in ALK2-related diseases, including brainstem glioma (DIPG), ependymoma, endometrial cancer, melanoma, non-small cell lung cancer, colorectal cancer, and pancreatic cancer.

• Smiles :

  O=C(NCCCN(C)C)C1=CC=C2N=C(C=3C=C(OC)C(OC)=C(OC)C3)N(C2=C1)C4CCC4

• Molecular Formula :

  C26H34N4O4

• Molecular Weight :

  466.573

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C

• CAS Number :

  3052084-77-9